# reload+after+2024-01-22 18:47:53.149751
address1§20 North Audley Street
city§London
zip§W1K 6LX
country§United Kingdom
phone§44 20 7788 7414
website§https://viraxbiolabs.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
fullTimeEmployees§11
companyOfficers§[{'maxAge': 1, 'name': 'Mr. James  Foster', 'age': 36, 'title': 'Chairman & CEO', 'yearBorn': 1987, 'fiscalYear': 2023, 'totalPay': 347500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason D. Davis', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2023, 'totalPay': 237500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark James Ternouth', 'age': 55, 'title': 'Chief Technical Officer & Director', 'yearBorn': 1968, 'fiscalYear': 2023, 'totalPay': 90000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Tomasz Evan George', 'age': 39, 'title': 'Chief Scientific Officer', 'yearBorn': 1984, 'fiscalYear': 2023, 'totalPay': 194000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nigel  McCracken M.Sc., Ph.D.', 'title': 'Chief Operating Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Joel  Yeung', 'title': 'Accounting Manager', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Clement  Monteil', 'title': 'Head of Scientific Research & Development', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Wang', 'title': 'Head of Procurement & Sourcing', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lily  Fu', 'title': 'Head of Supply Chain', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
priceToSalesTrailing12Months§268.73672
currency§USD
dateShortInterest§1702598400
forwardEps§-1.9
exchange§NCM
quoteType§EQUITY
shortName§Virax Biolabs Group Limited
longName§Virax Biolabs Group Limited
firstTradeDateEpochUtc§1658410200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4a944c5c-f1d1-3041-8c4c-e4a3baeb60d2
gmtOffSetMilliseconds§-18000000
targetHighPrice§20.0
targetLowPrice§20.0
targetMeanPrice§20.0
targetMedianPrice§20.0
recommendationKey§none
numberOfAnalystOpinions§1
quickRatio§10.35
grossMargins§-0.15944
ebitdaMargins§0.0
trailingPegRatio§None
